98%
921
2 minutes
20
Background: Several ablation confirmation software methods for minimum ablative margin assessment have recently been developed to improve local outcomes for patients undergoing thermal ablation of colorectal liver metastases. Previous assessments were limited to single institutions mostly at the place of development. The aim of this study was to validate the previously identified 5 mm minimum ablative margin (A0) using autosegmentation and biomechanical deformable image registration in a multi-institutional setting.
Methods: This was a multicentre, retrospective study including patients with colorectal liver metastases undergoing CT- or ultrasound-guided microwave or radiofrequency ablation during 2009-2022, reporting 3-year local disease progression (residual unablated tumour or local tumour progression) rates by minimum ablative margin across all institutions and identifying an intraprocedural contrast-enhanced CT-based minimum ablative margin associated with a 3-year local disease progression rate of less than 1%.
Results: A total of 400 ablated colorectal liver metastases (median diameter of 1.5 cm) in 243 patients (145 men; median age of 62 [interquartile range 54-70] years) were evaluated, with a median follow-up of 26 (interquartile range 17-40) months. A total of 119 (48.9%) patients with 186 (46.5%) colorectal liver metastases were from international institutions B, C, and D that were not involved in the software development. Three-year local disease progression rates for 0 mm, >0 and <5 mm, and 5 mm or larger minimum ablative margins were 79%, 15%, and 0% respectively for institution A (where the software was developed) and 34%, 19%, and 2% respectively for institutions B, C, and D combined. Local disease progression risk decreased to less than 1% with an intraprocedurally confirmed minimum ablative margin greater than 4.6 mm.
Conclusion: A minimum ablative margin of 5 mm or larger demonstrates optimal local oncological outcomes. It is proposed that an intraprocedural minimum ablative margin of 5 mm or larger, confirmed using biomechanical deformable image registration, serves as the A0 for colorectal liver metastasis thermal ablation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364140 | PMC |
http://dx.doi.org/10.1093/bjs/znae165 | DOI Listing |
Ther Innov Regul Sci
August 2025
Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, United States of America.
Background: Cardiovascular and oncology trials increasingly require large sample sizes and long follow-up periods. Several approaches have been developed to optimize sample size including sample size re-estimation based on the promising zone approach. With time-to-event endpoints, methods traditionally used to test for treatment effects are based on proportional hazards assumptions, which may not always hold.
View Article and Find Full Text PDFCan J Neurol Sci
August 2025
Kentucky Neuroscience Institute (KNI), UK Comprehensive Epilepsy Program, Department of Neurosurgery, University of Kentucky, Lexington, KY, USA.
Background: Hypothalamic hamartomas (HHs) are a known cause of refractory focal epilepsy. Advancement in microsurgical techniques and introduction of stereotactic ablative methods have led to improved complication rates, but the effect on seizure control is still to be determined. In this systematic review, we present a thorough analysis of published literature on the outcomes of various surgical treatments of HHs for refractory epilepsy.
View Article and Find Full Text PDFEur Radiol
July 2025
Department of Radiology, Seoul National University Hospital, Seoul, Korea.
Objectives: To evaluate the outcomes of yttrium-90 radioembolization (glass microspheres) in patients with unilobar hepatocellular carcinoma (HCC) and portal vein invasion (PVI) who have preserved liver function.
Materials And Methods: This study included 48 patients with unilobar HCC and PVI, all with Child-Pugh A, treated with radioembolization at a single institution between January 2016 and December 2023. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and localized mRECIST.
BMJ Open
July 2025
Institut de Cancerologie de l'Ouest Saint Herblain, Saint-Herblain, Pays de la Loire, France
Introduction: Salvage prostatic bed radiotherapy (PBRT) is a standard in case of biochemical recurrence following radical prostatectomy (RP) for prostate cancer (PC). The management of isolated prostatic bed recurrence following RP and PBRT is debated. Reirradiation within stereotactic body radiotherapy (SBRT) guided by metabolic imaging could be a relevant option in this case.
View Article and Find Full Text PDFRadiother Oncol
August 2025
Department of Radiation Oncology, Centre Eugène Marquis, Ille-et-Vilaine, Rennes, France.
Objectives: Stereotactic ablative radiotherapy (SABR) is a relevant option for the radical treatment of lung metastases from colorectal cancer with insufficient local control in some cases. The aim of this study is to determine the dosimetric and clinical predictive factors affecting the efficacy of SABR in treating lung metastases from colorectal cancer.
Materials And Methods: Patients with lung metastases from colorectal cancer treated with SABR in 8 centers between August 2016 and January 2023 were consecutively reviewed.